JUNE 1, 2023
Forward Looking Statements and Other Cautions This presentation may include forward- looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, industry environment, potential growth opportunities, and our expectations for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” or the negative version of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors in our filings made with the Securities and Exchange Commission (the “SEC”), including our 2022 Form 10-K filed with the SEC on March 8, 2023 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, expected to be filed with the SEC on May 9, 2023. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations. This presentation may also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumption, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. By receiving this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and our market position and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of our business.
Technology platform designed to customize bunion and midfoot correction procedures via intelligent planning and patient-specific cut guides Transaction Overview Upfront Cash $20 million Potential Milestone Payments $10 million Transaction Asset Purchase Assets Technology for Pre-Operative Planning and PSI Guides Patent Applications 22 FDA Status 510(k) Clearance
Pre-Operative Planning Patient-Specific Cut Guide Customized Intra-Operative Assistance AI-enabled software utilizes the patient’s CT scan data to create a 3D plan for correcting the patient’s deformity A patient-specific, 3D-printed cut guide is produced, customized to fit the patient’s unique foot anatomy The patient-specific guide and associated instrumentation are designed to streamline surgical approach for accurate, corrective cuts Technology Summary – RedPoint Medical 3D
Complements Our Business Strategy Industry’s Only Bunion-Focused Direct Sales Channel Rapid, Focused Innovation Highly Effective Surgeon Education Compelling Lapiplasty® Clinical Outcomes Comprehensive Direct-to-Patient Education Technologies complement our rapid, focused innovation approach to advance Lapiplasty® & Adductoplasty® therapies, with opportunity to further enhance surgeon & patient education and optimize clinical outcomes
Synergies for Future Growth “We believe there are excellent synergies with RedPoint’s FDA cleared technologies and our Lapiplasty® and Adductoplasty® procedures that strengthen our market leadership and accelerate our competitive differentiation, as we advance our mission to improve surgical outcomes for patients suffering from bunion and related midfoot deformities,” said John T. Treace. Development of automation for efficiency and scalability Technology platform supporting future innovation Opportunity for incremental growth of blended ASP Potential to expand active surgeon user base Designed to improve surgical efficiency and patient outcomes Opportunity for differentiated supportive clinical evidence Research & Development Expansion Expanded Revenue Opportunities Continued Focus on Patient Outcomes
